Perceptions about Research Participation among Individuals at Risk and Individuals with Premanifest Huntington's Disease: A Survey Conducted by the European Huntington Association.
Huntington’s disease
clinical research
clinical trials
premanifest Huntington’s disease
survey
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
20 Aug 2021
20 Aug 2021
Historique:
received:
19
07
2021
revised:
13
08
2021
accepted:
18
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
There has been great progress in Huntington's disease (HD) research. Yet, effective treatments to halt disease before the onset of disabling symptoms are still unavailable. Scientific breakthroughs require an active and lasting commitment from families. However, they are traditionally less involved and heard in studies. Accordingly, the European Huntington Association (EHA) surveyed individuals at risk (HDRisk) and with premanifest HD (PreHD) to determine which factors affect their willingness to participate in research. Questions assessed research experience and knowledge, information sources, reasons for involvement and noninvolvement, and factors preventing and facilitating participation. The survey included 525 individuals, of which 68.8% never participated in studies and 38.6% reported limited research knowledge. Furthermore, 52% trusted patient organizations to get research information. Reasons for involvement were altruistic and more important than reasons for noninvolvement, which were related to negative emotions. Obstacles included time/financial constraints and invasive procedures, while professional support was seen as a facilitator. PreHD individuals reported less obstacles to research participation than HDRisk individuals. Overall, a high motivation to participate in research was noted, despite limited experience and literacy. This motivation is influenced by subjective and objective factors and, importantly, by HD status. Patient organizations have a key role in fostering motivation through education and support.
Identifiants
pubmed: 34442459
pii: jpm11080815
doi: 10.3390/jpm11080815
pmc: PMC8400079
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : F. Hoffmann-La Roche
ID : EPBA2597097-A46
Références
AJOB Empir Bioeth. 2020 Jul-Sep;11(3):160-171
pubmed: 32516056
Eur J Hum Genet. 2016 Oct;24(10):1396-402
pubmed: 27165004
J Huntingtons Dis. 2019;8(1):79-85
pubmed: 30689592
Alzheimers Res Ther. 2010 Dec 21;2(6):34
pubmed: 21172069
Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):75-92
pubmed: 27174011
Trials. 2017 Sep 29;18(1):444
pubmed: 28962634
Neurology. 2013 Sep 24;81(13):1141-7
pubmed: 23966256
Mov Disord. 2020 Dec;35(12):2193-2200
pubmed: 32686867
Mov Disord. 2014 Sep 15;29(11):1335-41
pubmed: 25164527
Arch Neurol. 2006 Jun;63(6):883-90
pubmed: 16769871
Expert Rev Neurother. 2019 Oct;19(10):983-995
pubmed: 31181964
J Parkinsons Dis. 2018;8(3):421-428
pubmed: 30010145
Clin Genet. 2013 Mar;83(3):221-31
pubmed: 22642570
Mov Disord. 2006 Mar;21(3):385-9
pubmed: 16211608
Intern Med J. 2013 May;43(5):531-40
pubmed: 21241441
JAMA. 2003 Sep 3;290(9):1219-20
pubmed: 12953009
J Genet Couns. 2007 Jun;16(3):347-62
pubmed: 17473962
Health Policy. 2012 Oct;107(2-3):231-42
pubmed: 22739128
IRB. 2003 Jan-Feb;25(1):11-6
pubmed: 12833900
Mov Disord. 2011 May;26(6):1127-33
pubmed: 21626556
J Alzheimers Dis. 2018;62(3):1079-1090
pubmed: 29562541
Ther Innov Regul Sci. 2015 Nov;49(6):929-939
pubmed: 26539338
N Engl J Med. 2019 Jun 13;380(24):2307-2316
pubmed: 31059641
J Huntingtons Dis. 2021;10(2):277-291
pubmed: 33646170
Clin Genet. 2019 Jul;96(1):28-34
pubmed: 31093973
PLoS Curr. 2011 Apr 12;3:RRN1230
pubmed: 21532913
PLoS One. 2015 May 26;10(5):e0128209
pubmed: 26010368
Mov Disord Clin Pract. 2016 Jun 22;4(2):212-224
pubmed: 30363395
Mov Disord. 2018 Feb;33(2):243-247
pubmed: 29205501
J Huntingtons Dis. 2015;4(2):131-40
pubmed: 26397894
Front Genet. 2018 Dec 10;9:624
pubmed: 30619456
Psychiatry Clin Neurosci. 2013 Jan;67(1):59-62
pubmed: 23331288
Neurotherapeutics. 2020 Oct;17(4):1645-1659
pubmed: 32705582
Semin Neurol. 2007 Apr;27(2):143-50
pubmed: 17390259
Neurology. 2020 May 12;94(19):e2045-e2053
pubmed: 32193209
Arch Neurol. 1998 Jun;55(6):801-5
pubmed: 9626771
PLoS Curr. 2011 Jun 14;2:RRN1244
pubmed: 21804956
Clin Genet. 2007 Feb;71(2):120-9
pubmed: 17250660
J Huntingtons Dis. 2019;8(4):421-430
pubmed: 31594242
J Huntingtons Dis. 2020;9(2):129-141
pubmed: 32065801
J Community Genet. 2020 Oct;11(4):421-432
pubmed: 32157658
Eur J Hum Genet. 2009 Mar;17(3):295-300
pubmed: 18781186
Contemp Clin Trials. 2018 Mar;66:74-79
pubmed: 29330082
Clin Trials. 2012 Dec;9(6):748-61
pubmed: 22942217